Efficacy and safety of finerenone in non-diabetic CKD patients: a single-center, real-world, retrospective study.

ABSTRACT:

Background

Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist, has shown promising efficacy and safety profiles in the management of chronic kidney disease (CKD) associated with type 2 diabetes mellitus (T2DM). However, evidence for its role in non-diabetic CKD patients require further investigation.

Methods

This retrospective, real-world study involved non-diabetic CKD patients from April 2023 to June 2024. Participants received finerenone alongside standard CKD treatment. Primary clinical results included changes in the urinary albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), and serum potassium (sK⁺) levels. The data were collected initially and during follow-ups at 1, 3, 6, and 12 months.

Results

In t

SUBMITTER: Li Y 

PROVIDER: S-EPMC12218821 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature